tirzepatide cardiovascular outcomes study In patients with type 2 diabetes and atherosclerotic disease, was noninferior to dulaglutide with respect to major cardiovascular events. , , Read the full SURPASS-CVOT Tirzepatide for Heart Failure with
Description
Syringe check: Are you using the right syringe size for your dose volume
Henry RR, Ratner RE, Stonehouse AH, et al
00032-X/asset/f312f4e3-50d1-472f-90c9-896e4cef8e23/main.assets/gr1_lrg.jpg)
Which is easiest to tolerate
In general, dose increases are typically spaced at least 4 weeks apart to help assess tolerability
This corresponded to a risk difference of 0.3% (95% CI 0.4% to 0.1%) and a hazard ratio of 0.82 (95% CI 0.74 to 0.91) (Fig
You have unmanaged cardiovascular conditions The glucagon receptor affects heart rate and blood pressure differently than GLP-1 alone
